Alexey V. Danilov, MD, PhD, discusses the efficacy seen in the ongoing phase 1b study examining the combination of zandelisib and zanubrutinib in patients with relapsed/refractory B-cell malignancies.
Alexey V. Danilov, MD, PhD, associate director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the efficacy seen in the ongoing phase 1b study (NCT02914938) examining the combination of zandelisib (ME-401) and zanubrutinib (Brukinsa) in patients with relapsed/refractory B-cell malignancies.
Findings from the study demonstrated an objective response rate was 100% with the combination of zandelisib and zanubrutinib in patients with B-cell malignancies, including follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, marginal zone lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma/high-grade B-cell lymphoma, Danilov says. Additionally, toxicities appeared favorable; however, grade 3 or higher cases of neutropenia and aspartate aminotransferase and alanine aminotransferase increase, Danilov says.
More data are necessary to fully understand the activity of the regimen, and whether the intermittent-dosing schedule will help overcome the potential risk of adverse events in patients, Danilov concludes.